Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 19/20 | 0.64 |
| ▸ | THRB | P10828 | 8/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.64 |
| ▸ | TGFBR2 | P37173 | 5/20 | 0.55 |
| ▸ | MAP3K20 | Q9NYL2 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4817309 | 0.89 | TGFBR1 (0.65) | TGFBR1THRBMAPK14TGFBR2MAP3K20 | |
| SCHEMBL6101101 | 0.86 | TGFBR1 (0.64) | TGFBR1THRBMAPK14TGFBR2MAP3K20 | |
| SCHEMBL4817287 | 0.81 | THRB (0.65) | TGFBR1THRBMAPK14TGFBR2MAP3K20 | |
| SCHEMBL18114967 | 0.81 | TGFBR1 (0.48) | TGFBR1THRBMAPK14TGFBR2 | |
| SCHEMBL4815752 | 0.80 | TGFBR1 (0.62) | TGFBR1THRBMAPK14TGFBR2MAP3K20 | |
| SCHEMBL18115005 | 0.80 | TGFBR1 (0.47) | TGFBR1THRBMAPK14TGFBR2MAP3K20 | |
| SCHEMBL18114961 | 0.79 | TGFBR1 (0.46) | TGFBR1THRBMAPK14TGFBR2 | |
| SCHEMBL411961 | 0.79 | TGFBR1 (0.85) | TGFBR1THRBMAPK14 | |
| SCHEMBL4823959 | 0.78 | TGFBR1 (0.60) | TGFBR1THRBMAPK14TGFBR2MAP3K20 | |
| SCHEMBL373535 | 0.78 | TGFBR1 (1.00) | TGFBR1THRBMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405299-B2 | Compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | claimed |
| EP-1567527-A1 | CONDENSED PYRAZOLO DERIVATIVES | ELI LILLY AND COMPANY (US) | 2005-08-31 | — | — | EP | claimed |
| WO-2004050659-A1 | NOVEL COMPOUNDS AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-06-17 | — | — | WO | claimed |
| US-7405299-B2 | Compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405299-B2 | Compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405299-B2 | Compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-03-16 | — | — | US | disclosed |
| EP-1567527-A1 | CONDENSED PYRAZOLO DERIVATIVES | ELI LILLY AND COMPANY (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050659-A1 | NOVEL COMPOUNDS AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | TGFB1, TGFB2, TGFBR1 | TGFBR1 3/4885THRB 318/4885MAPK14 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.